311 related articles for article (PubMed ID: 28403849)
1. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
Tijnagel MJ; Scheepe JR; Blok BF
BMC Urol; 2017 Apr; 17(1):30. PubMed ID: 28403849
[TBL] [Abstract][Full Text] [Related]
2. Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder.
Tanaka Y; Tanuma Y; Masumori N
Int J Urol; 2016 Oct; 23(10):866-872. PubMed ID: 27520420
[TBL] [Abstract][Full Text] [Related]
3. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
5. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Actas Urol Esp; 2016 Mar; 40(2):96-101. PubMed ID: 26556482
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
Wang CC; Kuo HC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
[TBL] [Abstract][Full Text] [Related]
7. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
8. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
[TBL] [Abstract][Full Text] [Related]
10. [Comprehensive pharmacologic management of overactive bladder].
Krivoborodov GG; Tur EI
Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
[TBL] [Abstract][Full Text] [Related]
11. Prospective open label study of solifenacin for overactive bladder in children.
Bolduc S; Moore K; Nadeau G; Lebel S; Lamontagne P; Hamel M
J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
[TBL] [Abstract][Full Text] [Related]
12. A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome.
Park J; Chun JY; Kim JH; Cheon SY; Song M; Choo MS; Lee KS; Oh SJ; Kim JC; Choi JB; Seo JT; Cho SY
Int Urol Nephrol; 2015 Feb; 47(2):235-42. PubMed ID: 25503446
[TBL] [Abstract][Full Text] [Related]
13. Long-term persistence with mirabegron in a real-world clinical setting.
Wada N; Watanabe M; Banjo H; Tsuchida M; Hori J; Tamaki G; Azumi M; Kita M; Kakizaki H
Int J Urol; 2018 May; 25(5):501-506. PubMed ID: 29651798
[TBL] [Abstract][Full Text] [Related]
14. [PROSPECTS FOR THE TREATMENT OF IDIOPATHIC AND NEUROGENIC OVERACTIVE BLADDER].
Kamalov AA; Korshunova ES; Popov GR; Khodyreva LA; Dudareva AA; Nizov AN
Urologiia; 2015; (1):30-2, 34-5. PubMed ID: 26094383
[TBL] [Abstract][Full Text] [Related]
15. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
Kinjo M; Sekiguchi Y; Yoshimura Y; Nutahara K
Low Urin Tract Symptoms; 2018 May; 10(2):148-152. PubMed ID: 27911988
[TBL] [Abstract][Full Text] [Related]
16. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective?
Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F
J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study.
Jiang F; Zhu L; Xu T; Gong MY; Huang YL; Li HF; Wang JJ; Tong XW; Cheng XX; Bai WP; Li X; Xu XX; Xu HC
Menopause; 2016 Apr; 23(4):451-7. PubMed ID: 26757270
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Hsiao SM; Lin HH; Kuo HC
Low Urin Tract Symptoms; 2018 Jan; 10(1):21-26. PubMed ID: 27515567
[TBL] [Abstract][Full Text] [Related]
19. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
Amarenco G; Sutory M; Zachoval R; Agarwal M; Del Popolo G; Tretter R; Compion G; De Ridder D
Neurourol Urodyn; 2017 Feb; 36(2):414-421. PubMed ID: 26714009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
